A Trial Evaluating Efficacy and Safety of Oxaliplatin With 5-Fluorouracil in Patients With Recurrent Ovarian Carcinoma
A Trial Evaluating Efficacy and Safety of Oxaliplatin With 5-Fluorouracil in Patients With Recurrent Ovarian Carcinoma
This is a Phase II study for recurrent ovarian carcinoma platinum-sensitive and resistant
 tumors Folfox regimen.
Evaluation of the safety and the efficacy of a combination of oxaliplatin and 5FU (Folfox) in
 patients with ovarian carcinoma relapsing either after platinum-combined regimen.

 The Folfox regimen is administered every 14 days. Evaluation of the toxicity is performed at
 each cycle and evaluation of the efficacy every 4 cycles of chemotherapy.
Inclusion Criteria:

 -  ovarian carcinoma relapse

 Exclusion Criteria:

 -  neurotoxicity grade III renal clearance < 60 ml/min